Project Grant HDTRA11710014

The University of Washington received a $229,870 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to develop and validate a novel plasma proteomic diagnostic for the detection of melioidosis. Melioidosis is a deadly tropical infection caused by the bacteria Burkholderia pseudomallei. The project aims to externally validate an 8-protein signature in plasma that preliminary studies have shown can accurately...

This Project Grant award for $216,165.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The funding supports research to characterize a conserved mono-heme cytochrome protein, tentatively designated "CytBP1", which is found in the pathogen Burkholderia pseudomallei and other disease-causing bacteria. The research aims to determine the structure and function of...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $813,450 to Case Western Reserve University to conduct research evaluating human T cells specific for Mycobacterium tuberculosis (MTB) antigens that are processed and presented by infected macrophages. The objective is to gain insight into which MTB antigens are presented and the composition and kinetics of the T cell repertoire targeting these...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $406,260 to Purdue University to develop a novel computational framework for B-cell epitope prediction. The project aims to build a comprehensive antigen database mapping immune selection profiles onto pathogen surfaces and develop a B-cell epitope predictor using innovative structural features and normalized selection statistics. This work...

This $534,000 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the role of antigen location, peptide:MHCII complex density, and complex half-life as drivers of CD4+ T cell differentiation. The research, conducted by the Children's Hospital of Philadelphia, aims to provide clarity on how the strength of "Signal 1" (antigen...

This federal Project Grant award of $451,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to The Trustees of Princeton University supports research to identify new antimicrobial targets in gram-negative bacterial pathogens using chemical synthetic lethality. The key objectives are to: 1) Identify a small molecule inhibitor of methionine synthase, a recently identified essential target in Burkholderia pseudomallei, when...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $785,511 to the University of Chicago to characterize individual and population-level variability in immune responses to Mycobacterium tuberculosis (TB) and influenza virus infections. The research will leverage induced pluripotent stem cell-derived macrophages to study the genetic and epigenetic factors...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $831,755 over 5 years to New York University (NYU) to conduct research on the role of lung-resident macrophage subsets in regulating type 2 immune responses and trained immunity. The research aims to elucidate the distinct functions of different macrophage populations, particularly nerve- and...

This Project Grant award of $472,210 was provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Massachusetts Medical School (UMASS Medical) to conduct research on T-cell mediated neutrophil recruitment during lung infections. The award period runs from June 23, 2025 to May 31, 2027. The primary objectives of this research project are to determine the spatiotemporal relationship between CD4+ resident...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $690,500 to Boston University Medical Campus to investigate the mechanisms underlying poor immune responses to the booster dose of the RTS,S malaria vaccine in African children. The key objectives are to: 1) identify specific antibody responses and functions that are suboptimal after the booster dose; 2)...